Growing Demand For Personalized Medicine Fueling The Growth Of The Market Due To Need For Tailored And Effective Treatments: Transformative Forces Shaping the Small Molecule Targeted Cancer Therapy Market Landscape in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Small Molecule Targeted Cancer Therapy Industry Market Size Be by 2025?
Recent years have seen substantial growth in the market for small molecule targeted cancer therapy. There is a projected increase from $78.07 billion in 2024, escalating to $85.35 billion in 2025, experiencing a compound annual growth rate (CAGR) of 9.3%. The ascension observed in the historical period stems from heightened comprehension of cancer biology, an increase in the sanctioning of inhibitors, escalating occurrence of cancer, adoption rate of personalized medicine rising early, and the broadening of oncology clinical trials.

What's the Long-Term Growth Forecast for the Small Molecule Targeted Cancer Therapy Market Size Through 2029?
The market for small molecule targeted cancer therapy is projected to experience robust growth in the upcoming years. It is forecasted to expand to a value of $120.35 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 9.0%. Factors facilitating the growth in the projection period include the rising demand for precision oncology, an increase in investment in next-generation inhibitors, elevated healthcare spending in emerging markets, growing demand for such therapies, and heightened strategic collaboration. Key trends for the forecasted period encompass focus on tumor-agnostic therapies, the evolution of allosteric modulators, the integration of artificial intelligence in drug discovery, the preference for oral targeted therapies, and a transition towards combination treatment methodologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/small-molecule-targeted-cancer-therapy-global-market-report

What Are the Key Growth Drivers Fueling the Small Molecule Targeted Cancer Therapy Market Expansion?
An increasing consumer preference for personalised healthcare is predicted to underpin the progress of the small molecule targeted therapy market in the future. This medical strategy customises disease prevention, diagnosis, and treatment to the unique traits of each patient, and is seeing a surge in demand due to the increasing necessity for therapies that enhance efficiency and minimise negative effects. By boosting the precision of treatment, optimising patient results, reducing detrimental side effects, and allowing treatments to be specially customised to patients' genetic and molecular composition, small molecule targeted therapy meets the rising demand for personalised medicine. As an example, in February 2024, the US-based non-profit organisation Personalized Medicine Coalition announced that in 2023, the US Food and Drug Administration (FDA) approved 16 new personalised treatments for patients with rare diseases - a significant step up from the 2022 figure of six. Consequently, this increasing preference for personalised medicine is fuelling the market growth of small molecule targeted therapy.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28331&type=smp

What Are the Key Trends Driving Small Molecule Targeted Cancer Therapy Market Growth?
Key players in the small molecule targeted cancer therapy market are honing in on innovative treatment methods, such as structure-based drug design, to create highly targeted inhibitors. These interventions specifically target abnormal oncogenic mutations, have less impact on non-target areas, and enhance patient results. The approach of structure-based drug design uses the three-dimensional shape of a target protein to devise small molecules that latch onto it accurately, amplifying the drug's effectiveness and diminishing adverse reactions. To illustrate, Mirati Therapeutics, an oncology company based in the US, disclosed KRAZATI (adagrasib) in December 2022 as a targeted treatment for adult patients suffering from locally advanced or metastatic KRAS G12C-mutated NSCLC who have previously undergone at least one authorized systemic therapy by the U.S. Food and Drug Administration (FDA). This authorization offers a fresh therapy alternative for patients struggling with hard-to-treat KRAS G12C-mutated non-small cell lung cancer, meeting a crucial unfulfilled medical requirement. KRAZATI functions by selectively inhibiting the KRAS G12C mutated protein, a key factor in cancer cell growth and survival.

How Is the Small Molecule Targeted Cancer Therapy Market Segmented?
The small molecule targeted cancer therapy market covered in this report is segmented as

1) By Therapy Type: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Histone Deacetylase Inhibitors, PARP Inhibitors, CDK Inhibitors, BCL-2 Inhibitors, mTOR Inhibitors, Other Small Molecule Inhibitors
2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Other Cancer Types
3) By Mode Of Administration: Oral, Intravenous, Other Modes
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Direct Sales
5) By End User: Hospitals, Specialty Clinics, Research Institutes, Other End Users

Subsegment:
1) By Tyrosine Kinase Inhibitors: EGFR Inhibitors, VEGFR Inhibitors, ALK Inhibitors, BCR-ABL Inhibitors, HER2 Inhibitors
2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib
3) By Histone Deacetylase Inhibitors: Pan-Histone Deacetylase Inhibitors, Class-specific Histone Deacetylase Inhibitors
4) By PARP Inhibitors: Olaparib, Niraparib, Rucaparib, Talazoparib
5) By CDK Inhibitors: CDK4/6 Inhibitors, CDK1/2 Inhibitors, Pan-CDK Inhibitors
6) By BCL-2 Inhibitors: Venetoclax, Navitoclax
7) By mTOR Inhibitors: Rapamycin Analogs (Rapalogs), ATP-competitive mTOR Inhibitors, Dual mTOR/PI3K Inhibitors
8) By Other Small Molecule Inhibitors: MEK Inhibitors, PI3K Inhibitors, RAF Inhibitors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28331&type=smp

Which Companies Are Leading the Charge in Small Molecule Targeted Cancer Therapy Market Innovation?
Major companies operating in the small molecule targeted cancer therapy market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis International AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., and Ipsen Biopharmaceuticals Inc.

Which Regions Are Leading the Global Small Molecule Targeted Cancer Therapy Market in Revenue?
North America was the largest region in the small molecule targeted cancer therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in small molecule targeted cancer therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28331

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.